#USA #Princeton #Ajinomoto #AJICAP #NJ Bio

NJ Bio and Ajinomoto Bio-Pharma Partner for Enhanced ADC Development

In a strategic move designed to foster innovation in biopharmaceutical development, NJ Bio, Inc. and Ajinomoto Bio-Pharma Services have officially announced their collaboration aimed at improving the accessibility and capabilities surrounding antibody-drug conjugates (ADCs). This partnership promises to significantly enhance the research and development landscape for biopharma innovators, enabling them to create more effective therapies.

NJ Bio, based in Princeton, New Jersey, has established itself as a vital player in the field of drug discovery and development. The company is well-regarded for its integrated services that guide clients from the early stages of drug design through to preclinical development. With this new collaboration, NJ Bio will incorporate Ajinomoto's AJICAP™ platform into its workflow, which is known for its site-specific conjugation technology.

Expanding Access to Innovative Technologies

Through the partnership, NJ Bio aims to take full advantage of the AJICAP™ platform, which allows for precise modifications of antibodies. This method not only preserves the structural integrity and functionality of antibodies but also enhances their pharmacokinetics and therapeutic index. By offering a highly reproducible, scalable solution, NJ Bio can provide its clients with an unprecedented approach to developing targeted therapeutics.

The AJICAP™ technology is distinguished by its scalability and compatibility with conventional antibody production processes, making it an ideal choice for researchers aiming to push the boundaries of current therapeutic options. NJ Bio’s integration of this technology will allow for the effective development of both cytotoxic and non-cytotoxic payloads.

Benefits to Clients in the Biopharma Sector

Clients of NJ Bio will reap significant advantages from this collaboration. With NJ Bio’s expertise in medicinal chemistry and biologics development, along with the precision offered by the AJICAP™ platform, biopharmaceutical companies can expect improved project outcomes and reduced risk during the development process. This partnership not only strengthens NJ Bio's service offerings but also positions the company as a comprehensive partner for biopharma businesses seeking end-to-end support.

Julien Dugal-Tessier, President and Chief Scientific Officer at NJ Bio, highlighted the importance of this collaboration, stating, "Expanding our capabilities with AJICAP™ aligns strongly with NJ Bio's mission to deliver cutting-edge, high-value solutions that accelerate our clients' discovery programs." This sentiment reflects NJ Bio's commitment to enhancing drug discovery and development processes across the industry.

Yasuyuki Otake, General Manager of Bio-Pharma Services at Ajinomoto, expressed enthusiasm for the collaboration, saying, "Together, we are enhancing the tools available to biopharma innovators to design and develop next-generation targeted therapies for patients." This mutual commitment to advancing medical science is likely to yield groundbreaking results in the realm of ADCs and related technologies.

Conclusion

The collaboration between NJ Bio, Inc. and Ajinomoto Bio-Pharma Services marks a pivotal moment in the field of biotechnology and drug development. As both companies work together to leverage the capabilities of AJICAP™, they are poised to empower researchers and biopharma companies in their quest for innovative, effective treatments. The improved development processes that stem from this collaboration could lead to more successful therapeutic initiatives, ultimately benefiting patients around the world.